A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Richly
H
H
University of Essen, West German Cancer Center, Essen, Germany.
Kupsch
P
P
Passage
K
K
Grubert
M
M
Hilger
R A
RA
Kredtke
S
S
Voliotis
D
D
Scheulen
M E
ME
Seeber
S
S
Strumberg
D
D
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D001219:Aspartate Aminotransferases / Q000494:pharmacology; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000077157:Sorafenib; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D004317:Doxorubicin; D000077157:Sorafenib; D001219:Aspartate Aminotransferases